Gilead's experimental drug fails mid-stage study

September 17, 2014 10:56 AM

5 0

Gilead's experimental drug fails mid-stage study

(Reuters) - Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening.

The mid-stage study evaluated the drug, simtuzumab, in combination with chemotherapy, against a placebo plus chemotherapy, in previously untreated patients with advanced pancreatic cancer.

Read more

To category page

Loading...